source
- PepGen's Phase 2 DM1 Data Show 46% Average Splicing Correction, Shares Jump 163%PepGen reported results from the 10 mg/kg multiple‑ascending‑dose cohort of its ongoing Phase 2 Freedom2‑DM1 trial, testing PGN‑EDODM1, an oligonucleotide designed to correct the molecular defect i…
- FDA requires GLP-1 drug labels to include warning about rare eye diseaseThe FDA has issued a directive to manufacturers of GLP-1 therapies, instructing them to revise product labeling. The label change must highlight an increased risk of a rare ocular condition that c…